LIVIVO - Search results -

Search results

Result 1 - 10 of total 672

Search options

Article ; Online: Correction for Zhi et al., "Cloning and Expression of the 44-Kilodalton Major Outer Membrane Protein Gene of the Human Granulocytic Ehrlichiosis Agent and Application of the Recombinant Protein to Serodiagnosis".

Zhi, N / Ohashi, N / Rikihisa, Y / Horowitz, H W / Wormser, G P / Hechemy, K

2023 Volume 61, Issue 10, Page(s) e0070323

Language	English
Publishing date	2023-09-07
Publishing country	United States
Document type	Journal Article ; Published Erratum
ZDB-ID	390499-4
ISSN	1098-660X ; 0095-1137
ISSN (online)	1098-660X
ISSN	0095-1137
DOI	10.1128/jcm.00703-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1188: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Semitauonic $b$-hadron decays

Bernlochner, Florian U. / Sevilla, Manuel Franco / Robinson, Dean J. / Wormser, Guy

A lepton flavor universality laboratory

2021

Abstract: The study of lepton flavor universality violation (LFUV) in semitauonic $b$-hadron decays has become increasingly important in light of longstanding anomalies in their measured branching fractions, and the very large datasets anticipated from the LHC and ...

Abstract	The study of lepton flavor universality violation (LFUV) in semitauonic $b$-hadron decays has become increasingly important in light of longstanding anomalies in their measured branching fractions, and the very large datasets anticipated from the LHC and Belle II. In this review, we undertake a comprehensive survey of the experimental environments and methodologies for semitauonic LFUV measurements at the $B$-factories and LHCb, along with a concise overview of the theoretical foundations and predictions for a wide range of semileptonic decay observables. We proceed to examine the future prospects to control systematic uncertainties down to the percent level, matching the precision of Standard Model (SM) predictions. Furthermore, we discuss new perspectives and caveats on combinations of the LFUV data and revisit the world averages for the ${\cal R}(D^{()})$ ratios. Here we demonstrate that different treatments for the correlations of uncertainties from $D^{}$ excited states can vary the current $3\sigma$ tension with the SM within a $1\sigma$ range. Prior experimental overestimates of $D^{*}\tau\nu$ contributions may further exacerbate this. The precision of future measurements is also estimated; their power to exploit full differential information, and solutions to the inherent difficulties in self-consistent new physics interpretations of LFUV observables, are briefly explored. Comment: Published version plus an additional subsection on the new R(Lc) results
Keywords	High Energy Physics - Experiment ; High Energy Physics - Phenomenology
Subject code	612
Publishing date	2021-01-20
Publishing country	us
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Hematogenous dissemination in early Lyme disease

Wormser, G. P.

Wiener Klinische Wochenschrift

2006 Volume 118, Issue 21-22, Page(s) 634

Language	German
Document type	Article
ZDB-ID	200462-8
ISSN	0043-5325
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 902: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Vaccination as a modality to prevent Lyme disease. A status report.

Wormser, G P

Infectious disease clinics of North America

1999 Volume 13, Issue 1, Page(s) 135–48, vii

Abstract: Recombinant outer surface protein A (OspA) of Borrelia burgdorferi is a highly protective immunogen for prevention of Lyme disease in experimental animals. Humoral immunity is sufficient for protection. The principal mechanism of action is prevention of ... ...

Abstract	Recombinant outer surface protein A (OspA) of Borrelia burgdorferi is a highly protective immunogen for prevention of Lyme disease in experimental animals. Humoral immunity is sufficient for protection. The principal mechanism of action is prevention of transmission of the spirochete from tick to host. A recombinant OspA vaccine has been licensed for use in dogs. The recent licensure of an OspA vaccine for humans resulted from a critical analysis of recently completed efficacy studies.
MeSH term(s)	Animals ; Antigens, Surface/genetics ; Antigens, Surface/immunology ; Bacterial Outer Membrane Proteins/genetics ; Bacterial Outer Membrane Proteins/immunology ; Bacterial Vaccines/administration & dosage ; Bacterial Vaccines/immunology ; Borrelia burgdorferi Group/immunology ; Clinical Trials as Topic ; Dogs ; Humans ; Lipoproteins ; Lyme Disease/prevention & control ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology
Chemical Substances	Antigens, Surface ; Bacterial Outer Membrane Proteins ; Bacterial Vaccines ; Lipoproteins ; OspA protein ; Vaccines, Synthetic
Language	English
Publishing date	1999-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1077676-x
ISSN	1557-9824 ; 0891-5520
ISSN (online)	1557-9824
ISSN	0891-5520
DOI	10.1016/s0891-5520(05)70047-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1187: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis.

Zhi, N / Ohashi, N / Rikihisa, Y / Horowitz, H W / Wormser, G P / Hechemy, K

Journal of clinical microbiology

2016 Volume 36, Issue 6, Page(s) 1666–1673

Abstract: A 44-kDa major outer membrane protein of the human granulocytic ehrlichiosis (HGE) agent is an immunodominant antigen in human infection. A gene encoding this protein was cloned and sequenced. Southern blot results revealed the existence of multigenes ... ...

Abstract	A 44-kDa major outer membrane protein of the human granulocytic ehrlichiosis (HGE) agent is an immunodominant antigen in human infection. A gene encoding this protein was cloned and sequenced. Southern blot results revealed the existence of multigenes homologous to the P44 gene in the genome of the HGE agent. The recombinant 44-kDa protein (rP44) was expressed by using expression vector pET30a. The reactivity of the affinity-purified rP44 was evaluated by Western immunoblot analysis and dot blot immunoassay. Western immunoblot analysis showed that mouse anti-rP44 serum reacted with 44- to 42-kDa proteins in six different HGE agent strains tested except strain 2, in which three proteins of 42, 40, and 38 kDa were recognized. Eleven HGE patient serum samples, a horse anti-HGE serum, and a horse anti-Ehrlichia equi serum recognized the rP44 protein. This suggests that rP44 is an HGE-E. equi group-specific antigen. Neither human anti-Ehrlichia chaffeensis serum nor rabbit anti-Borrelia burgdorferi serum reacted with rP44. Sera from two patients coinfected with the HGE agent and B. burgdorferi reacted positively with rP44 and the HGE agent. Sera from 20 HGE patients with indirect fluorescent-antibody (IFA) titers ranging from 1:20 to 1:2,560 gave distinct positive reactions in a dot immunoblot assay. There was a positive correlation between the color densities of the dot reactions and the IFA titers when greater than 50 ng of recombinant antigen per dot was used. The use of the affinity-purified rP44 protein as antigen would provide a more specific, consistent, and simpler serodiagnosis for HGE than the use of whole infected cells or purified HGE agents.
MeSH term(s)	Amino Acid Sequence ; Animals ; Antibodies, Bacterial/blood ; Antigens, Bacterial/chemistry ; Antigens, Bacterial/genetics ; Antigens, Bacterial/immunology ; Bacterial Outer Membrane Proteins/genetics ; Bacterial Outer Membrane Proteins/immunology ; Blotting, Western ; Cloning, Molecular ; Ehrlichia/genetics ; Ehrlichia/immunology ; Ehrlichia/isolation & purification ; Ehrlichiosis/diagnosis ; Electrophoresis, Polyacrylamide Gel ; Granulocytes/microbiology ; Humans ; Immunoblotting/methods ; Mice ; Multigene Family ; Rabbits ; Recombinant Proteins/chemistry ; Recombinant Proteins/genetics ; Recombinant Proteins/immunology ; Sensitivity and Specificity ; Sequence Analysis, DNA
Chemical Substances	Antibodies, Bacterial ; Antigens, Bacterial ; Bacterial Outer Membrane Proteins ; Recombinant Proteins
Language	English
Publishing date	2016-01-07
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	390499-4
ISSN	1098-660X ; 0095-1137
ISSN (online)	1098-660X
ISSN	0095-1137
DOI	10.1128/JCM.36.6.1666-1673.1998
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1188: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Co-infection with HIV-I and HTLV-I/II In Intravenous Drug Users in Suburban New York City, With Comparison to Other Geographic Areas.

Wormser, G P / Cannon, R O / Hartley, T M / Forseter, G / Horowitz, H / Nadelman, R B

Leukemia & lymphoma

2016 Volume 3, Issue 5-6, Page(s) 435–438

Abstract: Co-infection with human T-lymphotropic virus types I or II (HTLV-I or -II) may be a cofactor in the progression of human immunodeficiency virus (HIV) infection. We assessed the frequency of simultaneous infection with these retroviruses among intravenous ...

Abstract	Co-infection with human T-lymphotropic virus types I or II (HTLV-I or -II) may be a cofactor in the progression of human immunodeficiency virus (HIV) infection. We assessed the frequency of simultaneous infection with these retroviruses among intravenous drug users from Westchester County, N.Y., a suburb of New York City. Comparison was made with similar studies in the United States and Europe.
Language	English
Publishing date	2016-07-27
Publishing country	United States
Document type	Journal Article
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.3109/10428199109070289
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prevention of Lyme borreliosis

Wormser, G. P.

Wiener Klinische Wochenschrift

2005 Volume 117, Issue 11-12, Page(s) 385

Language	German
Document type	Article
ZDB-ID	200462-8
ISSN	0043-5325
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 902: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination.

Wormser, G P

Seminars in neurology

1997 Volume 17, Issue 1, Page(s) 45–52

Abstract: Antibiotic therapy is recommended for all forms of neuroborreliosis. Although stage 2 neuroborreliosis will usually resolve without any treatment, antibiotic therapy has been associated with faster resolution of symptoms and may prevent additional non- ... ...

Abstract	Antibiotic therapy is recommended for all forms of neuroborreliosis. Although stage 2 neuroborreliosis will usually resolve without any treatment, antibiotic therapy has been associated with faster resolution of symptoms and may prevent additional non-neurologic disease manifestations. Ceftriaxone is the most convenient parenteral agent for stage 2 and 3 neuroborreliosis because of its once-daily dosage. Available data indicate that a 2-4-week treatment course is adequate for most patients. Patients with isolated seventh nerve palsy may be treated with an oral agent (for example, doxycycline). Recombinant outer surface protein A of Borrelia burgdorferi is a highly protective immunogen for prevention of Lyme disease in experimental animals. Humoral immunity is sufficient for protection. A recombinant OspA vaccine has been licensed for prevention of Lyme disease in dogs. Licensure of an OspA vaccine for humans will depend on a critical analysis of the results of recently completed efficacy studies.
MeSH term(s)	Animals ; Anti-Bacterial Agents/therapeutic use ; Bacterial Vaccines ; Borrelia burgdorferi Group/immunology ; Dogs ; Humans ; Lyme Disease/complications ; Lyme Disease/prevention & control ; Lyme Disease/therapy ; Nervous System Diseases/drug therapy ; Nervous System Diseases/etiology
Chemical Substances	Anti-Bacterial Agents ; Bacterial Vaccines
Language	English
Publishing date	1997-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	603165-1
ISSN	1098-9021 ; 0271-8235
ISSN (online)	1098-9021
ISSN	0271-8235
DOI	10.1055/s-2008-1040912
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1737: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease.

Wormser, G P

Infection

1996 Volume 24, Issue 2, Page(s) 178–181

Abstract: Unanswered questions in the management of patients with Lyme disease or those who have had Ixodes tick bites include: Is antimicrobial therapy effective in preventing Lyme disease during the incubation period of the infection? Which oral agents are most ... ...

Abstract	Unanswered questions in the management of patients with Lyme disease or those who have had Ixodes tick bites include: Is antimicrobial therapy effective in preventing Lyme disease during the incubation period of the infection? Which oral agents are most effective in treatment of Lyme disease? Are macrolides efficacious? And, for how long a time period should antimicrobial therapy be given? Potentially useful insights into these questions can be gained by examining experience with other spirochetal infections. Using this information, in conjunction with existing data from recent studies on Lyme borreliosis, tentative answers to these questions can be formulated. Based on this analysis, it would be anticipated that a short course of antibiotic therapy, perhaps even a single dose, will be effective in preventing Lyme disease after a tick bite. Beta-lactam antibiotics such as amoxicillin, and tetracycline preparations, such as doxycycline, are the mainstays of oral therapy for treatment of active infection. Macrolides are less effective, but their utility is likely to be improved if they are given in maximal dosage. There is no convincing evidence for extending treatment of early Lyme disease beyond 14 days. There is also no evidence that longer therapy is more efficacious for other manifestations of Lyme disease, although this issue deserves further study.
MeSH term(s)	Administration, Oral ; Amoxicillin/therapeutic use ; Animals ; Anti-Bacterial Agents/therapeutic use ; Bites and Stings/drug therapy ; Bites and Stings/microbiology ; Clinical Protocols ; Doxycycline/therapeutic use ; Humans ; Lyme Disease/drug therapy ; Lyme Disease/prevention & control ; Macrolides ; Penicillins/therapeutic use ; Tetracyclines/therapeutic use ; Ticks/microbiology
Chemical Substances	Anti-Bacterial Agents ; Macrolides ; Penicillins ; Tetracyclines ; Amoxicillin (804826J2HU) ; Doxycycline (N12000U13O)
Language	English
Publishing date	1996-03
Publishing country	Germany
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/bf01713335
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Lyme disease vaccine.

Wormser, G P

Infection

1996 Volume 24, Issue 2, Page(s) 203–207

Abstract: Subunit vaccines consisting of single recombinant outer surface proteins (Osp) of Borrelia burgdorferi have been highly successful in protecting mice against challenge by borrelial strains closely related to the strain from which the immunogen was ... ...

Abstract	Subunit vaccines consisting of single recombinant outer surface proteins (Osp) of Borrelia burgdorferi have been highly successful in protecting mice against challenge by borrelial strains closely related to the strain from which the immunogen was derived. Humoral immunity is sufficient for protection. A dual mode of action for these vaccines has been suggested because serum factors ingested by the tick during the blood meal may begin to reduce the spirochete inoculum prior to transmission to the host. At present two different recombinant OspA vaccine preparations (monovalent) are being evaluated in humans in large-scale phase III efficacy trials in the United States. Local discomfort at the intramuscular injection site has been the principal adverse effect seen to date with these vaccines, but further data on safety are being collected. The greater heterogeneity of OspA among Lyme Borrelia in Europe implies that a vaccine preparation containing multiple antigens (multivalent) may be necessary there, although this is also a concern in the United States.
MeSH term(s)	Animals ; Antigens, Surface ; BCG Vaccine/immunology ; Bacterial Outer Membrane Proteins ; Bacterial Vaccines ; Borrelia burgdorferi Group/immunology ; Cricetinae ; Dogs ; Humans ; Immunity, Active ; Immunization, Passive ; Lipoproteins ; Lyme Disease/prevention & control ; Mice ; Ticks/microbiology ; Vaccines, Inactivated ; Vaccines, Synthetic
Chemical Substances	Antigens, Surface ; BCG Vaccine ; Bacterial Outer Membrane Proteins ; Bacterial Vaccines ; Lipoproteins ; OspA protein ; Vaccines, Inactivated ; Vaccines, Synthetic
Language	English
Publishing date	1996-03
Publishing country	Germany
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/bf01713340
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito